259 related articles for article (PubMed ID: 7232966)
1. [Long-term results of treatment of Parkinson's disease with bromocriptine and domperidone (author's transl)].
Agid Y; Quinn N; Lhermitte F
Rev Neurol (Paris); 1981; 137(1):49-51. PubMed ID: 7232966
[TBL] [Abstract][Full Text] [Related]
2. [Improved therapeutic response to L-dopa in Parkinson's disease, when combined with bromocriptine (author's transl)].
Ulm G
Nervenarzt; 1981 Feb; 52(2):116-20. PubMed ID: 7219619
[No Abstract] [Full Text] [Related]
3. [Comparative studies of L-DOPA alone and combination with a peripheral DOPA decarboxylase inhibitor, HCL-benserazide, on Parkinson's disease-part I: clinical aspects (author's transl)].
Yokochi M; Kondo T; Hirayama K; Narabayashi H; Kuruma I
No To Shinkei; 1979 Mar; 31(3):295-304. PubMed ID: 444336
[No Abstract] [Full Text] [Related]
4. [CB 154 in the treatment of Parkinson's disease. Results in combination with L-dopa and decarboxylase inhibitor].
Meco G; Casacchia M; Zamponi A; Agnoli A
Acta Neurol (Napoli); 1976; 31(4):479-48. PubMed ID: 1037427
[No Abstract] [Full Text] [Related]
5. [Comparative studies of L-DOPA alone and combination with a peripheral DOPA decarboxylase inhibitor, benserazide-HCl, on Parkinson's disease--Part II: Pharmacokinetic study (author's transl)].
Yokochi M; Kondo T; Hirayama K; Narabayashi H; Kuruma I
No To Shinkei; 1979 Apr; 31(4):339-48. PubMed ID: 454549
[No Abstract] [Full Text] [Related]
6. Treatment of parkinson's disease with bromocriptine.
Lieberman A; Kupersmith M; Estey E; Goldstein M
N Engl J Med; 1976 Dec; 295(25):1400-4. PubMed ID: 989885
[TBL] [Abstract][Full Text] [Related]
7. [Bromocriptine in Parkinsonian syndromes. Results obtained in a group of patients treated for 8 months].
Quattrini A; Paggi A; Del Pesce M; Di Bella P
Riv Patol Nerv Ment; 1978; 99(3):150-63. PubMed ID: 752907
[TBL] [Abstract][Full Text] [Related]
8. A nation-wide collaborative study on the long-term effects of bromocriptine in patients with Parkinson's disease. First interim report in Japan.
Nakanishi T; Mizuno Y; Goto I; Iwata M; Kanazawa I; Kowa H; Mannen T; Nishitani H; Ogawa N; Takahashi A
Eur Neurol; 1988; 28 Suppl 1():3-8. PubMed ID: 3378560
[TBL] [Abstract][Full Text] [Related]
9. A double-blind study of bromocriptine and L-dopa in de novo Parkinson's disease. Short-term results.
Riopelle RJ; Gawel MJ; Libman I; King DB; McLean DR; Paulseth R; Raphy B; Bouchard S
Eur Neurol; 1988; 28 Suppl 1():11-4. PubMed ID: 3288477
[TBL] [Abstract][Full Text] [Related]
10. [The L-dopa test in Parkinson's disease].
Esteguy M; Bonnet AM; Kefalos J; Lhermitte F; Agid Y
Rev Neurol (Paris); 1985; 141(5):413-5. PubMed ID: 4048732
[TBL] [Abstract][Full Text] [Related]
11. [Secondary effects of prolonged levodopa therapy in Parkinson's disease].
Peiró Grasa A; Grau-Veciana JM
Med Clin (Barc); 1985 Jun; 85(3):88-91. PubMed ID: 4021630
[No Abstract] [Full Text] [Related]
12. [Psychological changes in parkinsonian patients during L-DOPA, amantidine, and L-DOPA + IDC treatment (author's transl)].
Puca FM; Megna GF; Masi G; Specchio LM
Riv Patol Nerv Ment; 1974 Oct; 95(5):676-84. PubMed ID: 4470268
[No Abstract] [Full Text] [Related]
13. [Pharmacokinetic and pharmacodynamic aspects of L-DOPA treatment and dopadecarboxilase inhibitors and dopaminergic antagonists in Parkinson's disease (author's transl)].
García de Yébenes J; Avila C; Bazán E; García E; Gervás J; Maseda C; Mena M; Muradas V; Ramos JA
Med Clin (Barc); 1982 Apr; 78(7):259-64. PubMed ID: 7087591
[No Abstract] [Full Text] [Related]
14. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
Hironishi M; Miwa H; Kondo T
No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758
[TBL] [Abstract][Full Text] [Related]
15. [Results after 3 to 5 years of treatment of 219 cases of Parkinson's syndrome treated by L-Dopa and an L-Dopa -decarboxylase inhibitor combination].
Boudin G; Pepin B; Guillard A; Godlewski S; Fabiani JM; Haguenau M
Rev Neurol (Paris); 1974; 130(7-8):273-84. PubMed ID: 4217929
[No Abstract] [Full Text] [Related]
16. [Development of studies on the treatment of parkinsonian syndromes with levodopa. II. Long-term effects of L-DOPA alone or in combination with a decarboxylase inhibitor].
Rabadeau Dumas JL; Rondot P; Cardon P
Therapie; 1977; 32(2):161-72. PubMed ID: 898124
[No Abstract] [Full Text] [Related]
17. "Long term evaluation of combined treatment of Parkinson disease with L-dopa, peripheral decarboxylase inhibitors and bromocreptine".
Caraceni T; Giovannini P; Girotti F; Parati E; Pederzoli M; Scigliano G
Ital J Neurol Sci; 1981 Dec; 2(4):337-42. PubMed ID: 7333824
[TBL] [Abstract][Full Text] [Related]
18. Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease.
Soykan I; Sarosiek I; Shifflett J; Wooten GF; McCallum RW
Mov Disord; 1997 Nov; 12(6):952-7. PubMed ID: 9399220
[TBL] [Abstract][Full Text] [Related]
19. [Bromocriptine as the 1st treatment of Parkinson's disease. Long term results].
Rascol A; Montastruc JL; Guiraud-Chaumeil B; Clanet M
Rev Neurol (Paris); 1982; 138(5):401-8. PubMed ID: 7146724
[TBL] [Abstract][Full Text] [Related]
20. L-dopa plus dopa-decarboxylase inhibitor. Sleep organization in Parkinson's syndrome before and after treatment.
Bergonzi P; Chiurulla C; Gambi D; Mennuni G; Pinto F
Acta Neurol Belg; 1975; 75(1):5-10. PubMed ID: 1202895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
